博拓生物(688767) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was ¥87,886,678.18, a decrease of 35.20% compared to ¥135,626,648.51 in the same period last year[3]. - Net profit attributable to shareholders was ¥8,732,428.90, down 77.97% from ¥39,631,348.59 year-on-year[3]. - The net profit after deducting non-recurring gains and losses was ¥6,374,531.32, reflecting an 83.84% decline from ¥39,439,732.29 in the previous year[3]. - The basic earnings per share were ¥0.08, down 78.95% from ¥0.38 in the same period last year[3]. - Net profit for Q1 2025 was ¥7,651,908.18, down 80.7% from ¥39,534,332.13 in Q1 2024[19]. - The company reported a total comprehensive income of ¥7,736,200.35 in Q1 2025, a decrease of 80.6% from ¥39,790,478.52 in Q1 2024[20]. Cash Flow and Assets - The net cash flow from operating activities decreased by 51.22%, amounting to ¥27,572,968.95 compared to ¥56,524,065.34 in the same period last year[3]. - Cash and cash equivalents at the end of Q1 2025 totaled ¥1,627,361,518.15, down from ¥1,765,712,542.46 at the end of Q1 2024[23]. - The company reported a net cash flow from investing activities of ¥549,667,150.86 in Q1 2025, compared to a negative cash flow of -¥158,167,545.39 in Q1 2024[23]. - The company achieved an investment cash inflow of ¥2,198,758,775.48 in Q1 2025, significantly higher than ¥10,015,205.48 in Q1 2024[23]. Expenses and Liabilities - Research and development expenses totaled ¥15,119,864.00, representing 17.20% of operating revenue, an increase of 6.40 percentage points from 10.80%[4]. - Total operating costs decreased to ¥81,933,026.26 in Q1 2025 from ¥91,142,982.46 in Q1 2024, representing a reduction of 10.0%[18]. - The total liabilities decreased from CNY 189,785,865.08 to CNY 119,507,669.73, a reduction of about 37.00%[15]. - The company reported a significant decrease in accounts payable from CNY 56,449,025.72 to CNY 42,610,289.36, a decline of approximately 24.55%[15]. Assets Overview - The total assets at the end of the reporting period were ¥2,543,737,243.69, a decrease of 2.24% from ¥2,602,132,040.91 at the end of the previous year[4]. - The company's current assets totaled CNY 1,820,532,780.18, down from CNY 1,877,922,689.10 at the end of 2024, indicating a decline of approximately 3.05%[13]. - Cash and cash equivalents increased to CNY 1,627,567,018.15 from CNY 1,590,964,931.16, reflecting a growth of about 2.33%[13]. - Accounts receivable decreased significantly from CNY 97,460,473.23 to CNY 67,092,116.03, representing a decline of approximately 31.14%[13]. - The company's equity attributable to shareholders increased slightly from CNY 2,409,476,107.01 to CNY 2,422,439,014.68, showing a growth of approximately 0.54%[16]. - The non-current assets totaled CNY 723,204,463.51, remaining relatively stable compared to CNY 724,209,351.81 at the end of 2024[14]. Market and Strategic Developments - The decline in operating revenue was primarily due to reduced government procurement in the U.S. market and cautious sales policies adopted by the company[7]. - The company reported a decrease in interest income and increased costs related to the employee stock ownership plan, contributing to the decline in net profit[7]. - The company has not reported any new product developments or market expansions during this period[11]. - There are no significant changes in the shareholder structure or any new strategic initiatives announced in the latest conference call[11]. - The total number of ordinary shareholders at the end of the reporting period was 6,212[9].